Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy

Nanotechnology has been the latest approach for diagnosis and treatment for cancer, which opens up a new alternative therapeutic drug delivery option to treat disease. Nanoparticles (NPs) display a broad role in cancer diagnosis and has various advantages over the other conventional chemotherapeutic...

Full description

Saved in:
Bibliographic Details
Published in:Seminars in cancer biology 2021-02, Vol.69, p.166-177
Main Authors: Raj, Sibi, Khurana, Sartaj, Choudhari, Ramesh, Kesari, Kavindra Kumar, Kamal, Mohammad Amjad, Garg, Neha, Ruokolainen, Janne, Das, Bhudev C., Kumar, Dhruv
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - administration & dosage
Antineoplastic Agents - pharmacokinetics
Cancer
Cancer diagnosis
Cancer therapeutics
Drug delivery
Drug Delivery Systems
Humans
Nanomedicine
Nanoparticles
Nanoparticles - administration & dosage
Nanoparticles - chemistry
Neoplasms - drug therapy
Neoplasms - pathology
Organ Specificity
Targeted therapy
Tissue Distribution
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nanotechnology has been the latest approach for diagnosis and treatment for cancer, which opens up a new alternative therapeutic drug delivery option to treat disease. Nanoparticles (NPs) display a broad role in cancer diagnosis and has various advantages over the other conventional chemotherapeutic drug delivery. NPs possess more specific and efficient drug delivery to the targeted tissue, cell, or organs and minimize the risk of side effects. NPs undergo passive and active mode of drug targets to tumor area with less elimination of the drug from the system. Size and surface characteristics of nanoparticles play a crucial role in modulating nanocarrier efficiency and the biodistribution of chemo drugs in the body. Several types of nanocarriers, such as polymers, dendrimers, liposome-based, and carbon-based, are studied widely in cancer therapy. Although FDA approved very few nanotechnology drugs for cancer therapy, a large number of studies are undergoing for the development of novel nanocarriers for potent cancer therapy. In this review, we discuss the details of the nano-based therapeutics and diagnostics strategies, and the potential use of nanomedicines in cancer therapy and cancer drug delivery.
ISSN:1044-579X
1096-3650
DOI:10.1016/j.semcancer.2019.11.002